Literature DB >> 33507403

Sub-adventitial divestment technique for resecting artery-involved pancreatic cancer: a retrospective cohort study.

Baobao Cai1, Zipeng Lu1, Markus W Büchler2, Yi Miao3,4, John P Neoptolemos1,5, Markus K Diener5, Mingna Li6, Lingdi Yin1, Yong Gao1, Jishu Wei1, Jianmin Chen1, Feng Guo1, Min Tu1, Chunhua Xi1, Junli Wu1, Wentao Gao1, Cuncai Dai1, Kuirong Jiang1.   

Abstract

PURPOSE: To introduce sub-adventitial divestment technique (SDT), a procedure to remove the tumor while preserving the artery during curative pancreatectomy. Peri-operative safety profile was also evaluated.
METHODS: In a single center consecutive series of pancreatectomy for pancreatic cancer, the outcome of patients who had pancreatectomy with SDT was compared to standard pancreatic surgery.
RESULTS: From June 2014 to June 2016, 72 patients had pancreatectomy with SDT and 235 had standard surgery. Tumor stage was T4 in all 72 (100%) tumors removed using SDT compared to four (2%) with standard pancreatectomy (p < 0.001). All 72 (100%) tumors in the SDT group were stage III compared to 24 (10%) in the standard surgery group (p < 0.001). Both groups had a high proportion of poorly differentiated tumors (52 (72%) and 163 (69%) respectively) and perineural tumor invasion (62 (86%) and 186 (79%) respectively). R1 (< 1 mm) was found in 24 (86%) of 28 tumors in the SDT group, and in 72 (60%) out of 120 standard pancreatectomy tumors (p = 0.01). Complications occurred in 29 (40%) of the SDT group and in 88 (37%) of the standard group. The in-hospital mortality was four (6%) in the SDT group and one (0.4%) in the standard group (p = 0.01), with a 90-day mortality of 5 (8%)/60 and 6 (3%)/209 (p = 0.07) respectively.
CONCLUSIONS: The sub-adventitial divestment technique appeared to be an effective surgical technique to remove the tumor while preserving the artery. This approach warrants further validation in prospective studies.

Entities:  

Keywords:  Arterial resection; Artery preservation; Pancreatectomy; Pancreatic neoplasms; Venous resection

Year:  2021        PMID: 33507403     DOI: 10.1007/s00423-021-02080-5

Source DB:  PubMed          Journal:  Langenbecks Arch Surg        ISSN: 1435-2443            Impact factor:   3.445


  26 in total

1.  Pretreatment assessment of resectable and borderline resectable pancreatic cancer: expert consensus statement.

Authors:  Mark P Callery; Kenneth J Chang; Elliot K Fishman; Mark S Talamonti; L William Traverso; David C Linehan
Journal:  Ann Surg Oncol       Date:  2009-04-24       Impact factor: 5.344

2.  Locally Advanced Pancreatic Cancer: Neoadjuvant Therapy With Folfirinox Results in Resectability in 60% of the Patients.

Authors:  Thilo Hackert; Milena Sachsenmaier; Ulf Hinz; Lutz Schneider; Christoph W Michalski; Christoph Springfeld; Oliver Strobel; Dirk Jäger; Alexis Ulrich; Markus W Büchler
Journal:  Ann Surg       Date:  2016-09       Impact factor: 12.969

3.  FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer.

Authors:  Thierry Conroy; Pascal Hammel; Mohamed Hebbar; Meher Ben Abdelghani; Alice C Wei; Jean-Luc Raoul; Laurence Choné; Eric Francois; Pascal Artru; James J Biagi; Thierry Lecomte; Eric Assenat; Roger Faroux; Marc Ychou; Julien Volet; Alain Sauvanet; Gilles Breysacher; Frédéric Di Fiore; Christine Cripps; Petr Kavan; Patrick Texereau; Karine Bouhier-Leporrier; Faiza Khemissa-Akouz; Jean-Louis Legoux; Béata Juzyna; Sophie Gourgou; Christopher J O'Callaghan; Claire Jouffroy-Zeller; Patrick Rat; David Malka; Florence Castan; Jean-Baptiste Bachet
Journal:  N Engl J Med       Date:  2018-12-20       Impact factor: 91.245

Review 4.  Borderline resectable pancreatic cancer: need for standardization and methods for optimal clinical trial design.

Authors:  Matthew H G Katz; Robert Marsh; Joseph M Herman; Qian Shi; Eric Collison; Alan P Venook; Hedy L Kindler; Steven R Alberts; Philip Philip; Andrew M Lowy; Peter W T Pisters; Mitchell C Posner; Jordan D Berlin; Syed A Ahmad
Journal:  Ann Surg Oncol       Date:  2013-02-23       Impact factor: 5.344

5.  Patterns of Recurrence After Resection of Pancreatic Ductal Adenocarcinoma: A Secondary Analysis of the ESPAC-4 Randomized Adjuvant Chemotherapy Trial.

Authors:  Robert P Jones; Eftychia-Eirini Psarelli; Richard Jackson; Paula Ghaneh; Christopher M Halloran; Daniel H Palmer; Fiona Campbell; Juan W Valle; Olusola Faluyi; Derek A O'Reilly; David Cunningham; Jonathan Wadsley; Suzanne Darby; Tim Meyer; Roopinder Gillmore; Alan Anthoney; Pehr Lind; Bengt Glimelius; Stephen Falk; Jakob R Izbicki; Gary William Middleton; Sebastian Cummins; Paul J Ross; Harpreet Wasan; Alec McDonald; Tom Crosby; Yuk Ting; Kinnari Patel; David Sherriff; Rubin Soomal; David Borg; Sharmila Sothi; Pascal Hammel; Markus M Lerch; Julia Mayerle; Christine Tjaden; Oliver Strobel; Thilo Hackert; Markus W Büchler; John P Neoptolemos
Journal:  JAMA Surg       Date:  2019-11-01       Impact factor: 14.766

6.  Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial.

Authors:  John P Neoptolemos; Daniel H Palmer; Paula Ghaneh; Eftychia E Psarelli; Juan W Valle; Christopher M Halloran; Olusola Faluyi; Derek A O'Reilly; David Cunningham; Jonathan Wadsley; Suzanne Darby; Tim Meyer; Roopinder Gillmore; Alan Anthoney; Pehr Lind; Bengt Glimelius; Stephen Falk; Jakob R Izbicki; Gary William Middleton; Sebastian Cummins; Paul J Ross; Harpreet Wasan; Alec McDonald; Tom Crosby; Yuk Ting Ma; Kinnari Patel; David Sherriff; Rubin Soomal; David Borg; Sharmila Sothi; Pascal Hammel; Thilo Hackert; Richard Jackson; Markus W Büchler
Journal:  Lancet       Date:  2017-01-25       Impact factor: 79.321

Review 7.  Borderline resectable pancreatic cancer: definitions, management, and role of preoperative therapy.

Authors:  Gauri R Varadhachary; Eric P Tamm; James L Abbruzzese; Henry Q Xiong; Christopher H Crane; Huamin Wang; Jeffrey E Lee; Peter W T Pisters; Douglas B Evans; Robert A Wolff
Journal:  Ann Surg Oncol       Date:  2006-07-24       Impact factor: 5.344

8.  Borderline resectable pancreatic cancer: the importance of this emerging stage of disease.

Authors:  Matthew H G Katz; Peter W T Pisters; Douglas B Evans; Charlotte C Sun; Jeffrey E Lee; Jason B Fleming; J Nicolas Vauthey; Eddie K Abdalla; Christopher H Crane; Robert A Wolff; Gauri R Varadhachary; Rosa F Hwang
Journal:  J Am Coll Surg       Date:  2008-03-17       Impact factor: 6.113

9.  The Impact of Positive Resection Margins on Survival and Recurrence Following Resection and Adjuvant Chemotherapy for Pancreatic Ductal Adenocarcinoma.

Authors:  Paula Ghaneh; Jorg Kleeff; Christopher M Halloran; Michael Raraty; Richard Jackson; James Melling; Owain Jones; Daniel H Palmer; Trevor F Cox; Chloe J Smith; Derek A O'Reilly; Jakob R Izbicki; Andrew G Scarfe; Juan W Valle; Alexander C McDonald; Ross Carter; Niall C Tebbutt; David Goldstein; Robert Padbury; Jennifer Shannon; Christos Dervenis; Bengt Glimelius; Mark Deakin; Alan Anthoney; Markus M Lerch; Julia Mayerle; Attila Oláh; Charlotte L Rawcliffe; Fiona Campbell; Oliver Strobel; Markus W Büchler; John P Neoptolemos
Journal:  Ann Surg       Date:  2019-03       Impact factor: 12.969

10.  Total Neoadjuvant Therapy With FOLFIRINOX in Combination With Losartan Followed by Chemoradiotherapy for Locally Advanced Pancreatic Cancer: A Phase 2 Clinical Trial.

Authors:  Janet E Murphy; Jennifer Y Wo; David P Ryan; Jeffrey W Clark; Wenqing Jiang; Beow Y Yeap; Lorraine C Drapek; Leilana Ly; Christian V Baglini; Lawrence S Blaszkowsky; Cristina R Ferrone; Aparna R Parikh; Colin D Weekes; Ryan D Nipp; Eunice L Kwak; Jill N Allen; Ryan B Corcoran; David T Ting; Jason E Faris; Andrew X Zhu; Lipika Goyal; David L Berger; Motaz Qadan; Keith D Lillemoe; Nilesh Talele; Rakesh K Jain; Thomas F DeLaney; Dan G Duda; Yves Boucher; Carlos Fernández-Del Castillo; Theodore S Hong
Journal:  JAMA Oncol       Date:  2019-07-01       Impact factor: 31.777

View more
  4 in total

Review 1.  Resection of Recurrent Pancreatic Cancer: Who Can Benefit?

Authors:  Henrik Nienhüser; Markus W Büchler; Martin Schneider
Journal:  Visc Med       Date:  2021-11-11

Review 2.  [Surgical treatment of pancreatic cancer-What is new?]

Authors:  Thomas Schmidt; Orlin Belyaev; Waldemar Uhl; Christiane J Bruns
Journal:  Chirurg       Date:  2022-03-31       Impact factor: 0.955

3.  Arterial Divestment and Resection in Post-neoadjuvant Pancreatic Adenocarcinoma.

Authors:  Yugal Limbu; Sujan Regmee; Roshan Ghimire; Dhiresh Kumar Maharjan; Prabin Bikram Thapa
Journal:  Cureus       Date:  2021-12-08

4.  Anatomy of the neural fibers at the superior mesenteric artery-a cadaver study.

Authors:  Michael D Reinehr; Raphael N Vuille-Dit-Bille; Christopher Soll; Anubhav Mittal; Jaswinder S Samra; Ralph F Staerkle
Journal:  Langenbecks Arch Surg       Date:  2022-05-03       Impact factor: 2.895

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.